Results 151 to 160 of about 61,613 (221)

Management of diarrhea in patients receiving liposomal irinotecan-based regimens: a narrative review of mechanisms, clinical impact, and evidence-based strategies. [PDF]

J Gastrointest Oncol
Zaniboni A.
europepmc   +1 more source

Engineered human adipose-derived stem cells delivering carboxylesterase and TRAIL for castration-resistant prostate cancer: Translational synthesis. [PDF]

Investig Clin Urol
Kim JH, Lee SH, Song YS.
europepmc   +1 more source

Long-Term Response and Survival With Liposomal Irinotecan and Fluorouracil in a Patient With Locally Advanced Pancreatic Ductal Adenocarcinoma: A Case Report. [PDF]

Cureus
Tulyte-Kirzova S, Vitkauskaite E, Gumbys L.   +2 more
europepmc   +1 more source

Efficacy and safety of liposomal irinotecan plus nimotuzumab in immune checkpoint inhibitor-refractory recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase II trial. [PDF]

EClinicalMedicine
He S, Bei WX, Lu N, Zhao ZY, Ye Y, Chen C, Tang L, Liu L, Lv S, Xiang YQ, Wang L.   +10 more
europepmc   +1 more source

Impact of prior conventional irinotecan use on nanoliposomal irinotecan efficacy in advanced pancreatic cancer: a meta-analysis. [PDF]

ESMO Open
Lee S, Correa TL, Birda V, Roshan K, Peters ML, Modest AM, Keko M, Bockorny B.   +7 more
europepmc   +1 more source

A single-arm phase II trial of <i>UGT1A1</i> genotype-guided high-dose irinotecan rechallenge in refractory metastatic colorectal cancer. [PDF]

Front Oncol
Kim H, Hong J, Kong SY, Choi MK.
europepmc   +1 more source

A patient-derived organ-on-a-chip platform for predicting chemotherapy response in locally advanced colorectal cancer. [PDF]

Bioeng Transl Med
Zhou H, Gu X, Chang W, Zhou L, Cao R, Wang X, Deng L, Xiao S, Ye S, Qian X, Xie Z, Li S, Xie X, Bai H.   +13 more
europepmc   +1 more source

Clinical Implications of <i>UGT1A1</i> Polymorphisms in Anticancer Therapy: An Updated Review. [PDF]

Pharmaceutics
Vitale SR, Drago M, Martorana F, Conti C, Massimino M, Stella S, Tomarchio C, Vigneri P, Manzella L.   +8 more
europepmc   +1 more source

Adjuvant mFOLFOXIRI after curative-intent resection of oligometastatic colorectal cancer: phase II FANTASTIC trial. [PDF]

BJS Open
Kataoka K, Yamada T, Yamazaki K, Kanaka S, Suto T, Shiozawa M, Takii Y, Yasui M, Yamaguchi T, Matsuhashi N, Takase N, Ito K, Spickard E, Fungtammasan A, Madhurapantula RS, Jurdi A, Oki E, Bando H, Nakamura Y, Yoshino T, Ikeda M, Mori K, Kanemitsu Y.   +22 more
europepmc   +1 more source

Epigallocatechin-3-Gallate, the green tea polyphenol suppresses expression of CD31 and VEGFR2 and enhances the chemotherapeutic potential of irinotecan in AOM/DSS model of colorectal cancer in mice. [PDF]

J Egypt Natl Canc Inst
Rahman SS, Baruah S, Akhtara N, Nath JK, Bharali MK.   +4 more
europepmc   +1 more source